Single-institution experience with 18F-DOPA and 68Ga-DOTA-TOC as a PET imaging tracer for peptide receptor radionuclide therapy in well-differentiated neuroendocrine neoplasms

#3277

Introduction: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor affinity with 68Ga-DOTA, is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). 18F-FDOPA tracer is also used in the diagnostic imaging of NENs, likely detecting additional lesions compared to 68Ga-DOTA.

Aim(s): To explore differences in tumor detection of both tracers and their relevance for PRRT patient selection.

Materials and methods: We retrospectively studied eight patients with NENs who underwent both 68Ga-DOTA-TOC and carbidopa-enhanced 18F-DOPA PET, before first-time PRRT. No routine scanning of either one tracer before the other was performed. All patients underwent both scans incidentally, due to stock availability or to detect suspected metastases with a second tracer. Treatment response was classified as partial response (PR), stable (SD), or progressive disease (PD), or undeterminable (UD).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Veenstra E, Noordzij W,

Keywords: neuroendocrine tumor, PET tracer, 18F-DOPA, 68Ga-DOTA-TOC, carbidopa, peptide receptor radionuclide therapy, PRRT,